Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
07:00am, Friday, 30'th Jan 2026
Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world ev
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
03:22pm, Thursday, 29'th Jan 2026
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026
12:26pm, Thursday, 29'th Jan 2026
Sanofi SNY reported fourth-quarter 2025 adjusted earnings of 89 cents per American depositary share, which beat the Zacks Consensus Estimate of 84 cents. Earnings of €1.53 per share rose 16.8% on a
Sanofi Creeps Higher On 'Essentially In Line' Guidance For 2026
09:28am, Thursday, 29'th Jan 2026
Sanofi stock rose slightly early Thursday on better-than-expected earnings and in line guidance for the current year.
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
06:31am, Thursday, 29'th Jan 2026
Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, th
Sanofi to Launch $1.20 Billion Share Buyback
01:58am, Thursday, 29'th Jan 2026
The buyback comes as the French drugmaker said that its sales and earnings for the fourth quarter rose.
Sanofi targets high single digit sales growth in 2026, plans share buyback
01:33am, Thursday, 29'th Jan 2026
French drugmaker Sanofi said on Thursday it expects sales to grow by a high-single-digit percentage in 2026, banking on strong demand for its blockbuster asthma drug Dupixent and some newer medicines.
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to r
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag
10:06am, Monday, 26'th Jan 2026
The FDA granted breakthrough status to Cogent's GIST drug combo after a trial showed it cut disease progression or death risk by 50% compared with current treatment.
Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema
01:29am, Friday, 23'rd Jan 2026
Sanofi said its amlitelimab drug confirmed its potential to treat eczema in patients 12 years and older in two late-phase studies.
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
01:00am, Friday, 23'rd Jan 2026
Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 wi
Sanofi CEO Paul Hudson: AI will change the cost and speed of drug development
02:30pm, Thursday, 22'nd Jan 2026
Sanofi CEO Paul Hudson discusses the impact of AI in the pharmaceutical space during an interview with CNBC at the World Economic Forum in Davos on Thursday.
Sanofi CEO Paul Hudson: AI will improve efficiency and change the cost and speed of drug development
09:14am, Thursday, 22'nd Jan 2026
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss state of the pharmaceutical landscape, future of drug pricing, drug pipeline, impact of AI, and more.
Press Release: Myqorzo and Redemplo approved in China
01:00am, Thursday, 15'th Jan 2026
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi's long-term commitment to C
Sanofi sees softness in U.S. vaccine demand in near term
02:23pm, Wednesday, 14'th Jan 2026
Sanofi chief executive Paul Hudson said on Wednesday the U.S. is likely to see a slight weakness in vaccine demand this year due to misinformation and heightened scrutiny under the current administrat
